



ASX Announcement

For immediate release

29 May 2009

CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine

Melbourne, Australia (29 May 2009) - CSL Limited (ASX:CSL), Australia's leading biopharmaceutical company, announced today that its US subsidiary, CSL Biotherapies, Inc., has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form. The vaccine will be manufactured at CSL's facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts. The new vaccine will be tested in clinical trials funded by HHS. The initial order under the contract will be for an amount of USD180 million.

The contract also provides HHS with the opportunity to use CSL's antigen filling and finishing capability at the company's manufacturing plants in Kankakee, Illinois and in Marburg, Germany.

CSL will maintain its commitment to supply seasonal influenza vaccines to Australia, the US and other markets. Consistent with the media release issued by the Australian Minister for Health and Ageing on 28 May 2009¹, CSL will also supply its Novel A (H1N1) vaccine to Australia.

"CSL's partnership with HHS to address the serious threat to public health that the A (H1N1) virus represents, is confirmation that we are a leader in the global influenza vaccines market," CEO Dr Brian McNamee said today. "In doing so, CSL will be applying more than 40 years of experience in developing and manufacturing influenza vaccines."

¹ Please refer to www.healthemergency.gov.au



ASX Announcement

Page 2

May 29, 2009

About CSL

Headquartered in Melbourne, Australia, CSL Limited is a global, specialty biopharmaceutical company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions.

With major facilities in Australia, Germany, Switzerland and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal year 2008, the company produced revenues of approximately A\$3.8 billion.

Media Contact:

Dr Rachel David
Director, Public Affairs
CSL Limited
Ph: +61 3 9389 1821
Email: rachel.david@csl.com.au

Investor Contact:

Mark Dehring
Head of Investor Relations
CSL Limited
Telephone: +61 3 9389 2818